
|Articles|December 12, 2022
Best Practices on Addressing Disparities and Practicing Multicultural Care in Myeloma
Advertisement
References:
- AACR Cancer Disparities Progress Report 2022: Achieving the Bold Vision of Health Equity for Racial and Ethnic Minorities and Other Underserved Populations. American Association for Cancer Research. 2022. Accessed October 11, 2022.
https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2022/06/AACR_CDPR_2022.pdf - An update on cancer deaths in the United States. Centers for Disease Control and Prevention. Updated February 28, 2022. Accessed October 12, 2022.
https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths/index.htm#print - Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. 2009;20(4):417-435. doi:10.1007/s10552-008-9256-0
- Moss JL, Pinto CN, Srinivasan S, Cronin KA, Croyle RT. Persistent poverty and cancer mortality rates: an analysis of county-level poverty designations. Cancer Epidemiol Biomarkers Prev. 2020;29(10):1949-1954. doi:10.1158/1055-9965.EPI-20-0007
- Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2016. National Cancer Institute; Surveillance, Epidemiology, and End Results Program. Updated April 9, 2020. Accessed October 10, 2022.
https://seer.cancer.gov/archive/csr/1975_2016/results_merged/sect_18_myeloma.pdf - Ailawadhi S, Aldoss IT, Yang D, et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012;158(1):91-98. doi:10.1111/j.1365-2141.2012.09124.x
- Scharff DP, Mathews KJ, Jackson P, Hoffsuemmer J, Martin E, Edwards D. More than Tuskegee: understanding mistrust about research participation. J Health Care Poor Underserved. 2010;21(3):879-97. doi:10.1353/hpu.0.0323.
- Brown EA, Bekker HL, Davison SN, Koffman J, Schell JO. Supportive care: communication strategies to improve cultural competence in shared decision making. Clin J Am Soc Nephrol. 2016;11(10):1902-1908. doi:10.2215/CJN.13661215
- Jayakrishnan TT, Bakalov V, Chahine Z, Lister J, Wegner RE, Sadashiv S. Disparities in the enrollment to systemic therapy and survival for patients with multiple myeloma. Hematol Oncol Stem Cell Ther. 2021;14(3):218-230. doi:10.1016/j.hemonc.2020.09.005
- Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: justum pretium--the just price. J Clin Oncol. 2013;31(28):3600-3604. doi:10.1200/JCO.2013.49.1845
- Dixit N, Rugo H, Burke NJ. Navigating a path to equity in cancer care: the role of patient navigation. Am Soc Clin Oncol Educ Book. 2021;41:1-8. doi:10.1200/EDBK_100026
- Creamer J, Shrider EA, Burns K, Chen F. Poverty in the United States: 2021. US Census Bureau. September 2022. Accessed October 12, 2022.
https://www.census.gov/content/dam/Census/library/publications/2022/demo/p60-277.pdf - Fiala MA, Wildes TM, Vij R. Racial disparities in the utilization of novel agents for frontline treatment of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(10):647-651. doi:10.1016/j.clml.2020.04.018
- Joshi H, Lin S, Fei K, et al. Multiple myeloma, race, insurance and treatment. Cancer Epidemiol. 2021;73:101974. doi:10.1016/j.canep.2021.101974
- Hu B, Boselli D, Pye LM, et al. Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphoma. Cancer. 2021;127(21):3991-3997. doi:10.1002/cncr.33779
- Rocque GB, Pisu M, Jackson BE, et al; Patient Care Connect Group. Resource use and Medicare costs during lay navigation for geriatric patients with cancer. JAMA Oncol. 2017;3(6):817-825. doi:10.1001/jamaoncol.2016.6307
- Roland KB, Milliken EL, Rohan EA, et al. Use of community health workers and patient navigators to improve cancer outcomes among patients served by federally qualified health centers: a systematic literature review. Health Equity. 2017;1(1):61-76. doi:10.1089/heq.2017.0001
- DeSalvo JM, Young GS, Krok-Schoen JL, Paskett ED. Characterizing time to diagnostic resolution after an abnormal cancer screening exam in older adult participants in the Ohio Patient Navigation Research Program. J Aging Health. 2018;30(8):1284-1304. doi:10.1177/0898264317715184
- Awidi M, Al Hadidi S. Participation of black Americans in cancer clinical trials: current challenges and proposed solutions. JCO Oncol Pract. 2021;17(5):265-271. doi:10.1200/OP.21.00001
- Saxton C, Cutforth A, Gonzalo B, Nichosl H, Fearnley K. Understanding barriers and facilitators to clinical trial participation among Black patients with multiple myeloma. J Clin Oncol. 2022;40(16):12137. doi:10.1200/JCO.2022.40.16_suppl.12137
- Saxton C, Cutforth A, Gonzalo B, et al. Understanding barriers and facilitators to clinical trial participation among Black patients with multiple myeloma. J Clin Oncol. 2022;40(suppl 16):12137. doi:10.1200/JCO.2022.40.16_suppl.12137
- Bhatnagar V, Gormley N, Kazandjian D, et al. FDA analysis of racial demographics in multiple myeloma trials. Blood. 2017;130(suppl 1):4352. doi:10.1182/blood.V130.Suppl_1.4352.4352
- Gormley N, Fashoyin-Aje L, Locke T, et al. Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare. Blood Cancer Discov. 2021;2(2):119-124. doi:10.1158/2643-3230.BCD-20-0123
- Kanapuru B, Fernandes LL, Fashoyin-Aje LA, et al. Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials. Blood Adv. 2022;6(6):1684-1691. doi:10.1182/bloodadvances.2021005482
- Quick facts. US Census Bureau. Accessed October 12, 2022.
https://www.census.gov/quickfacts/fact/table/US/RHI125221
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5




































